229 related articles for article (PubMed ID: 20538374)
1. Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo.
Darreh-Shori T; Forsberg A; Modiri N; Andreasen N; Blennow K; Kamil C; Ahmed H; Almkvist O; Långström B; Nordberg A
Neurobiol Aging; 2011 Dec; 32(12):2320.e15-32. PubMed ID: 20538374
[TBL] [Abstract][Full Text] [Related]
2. The apolipoprotein E ε4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase.
Darreh-Shori T; Modiri N; Blennow K; Baza S; Kamil C; Ahmed H; Andreasen N; Nordberg A
Neurobiol Aging; 2011 Jul; 32(7):1236-48. PubMed ID: 19713000
[TBL] [Abstract][Full Text] [Related]
3. Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism.
Darreh-Shori T; Brimijoin S; Kadir A; Almkvist O; Nordberg A
Neurobiol Dis; 2006 Nov; 24(2):326-33. PubMed ID: 16973370
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease.
Darreh-Shori T; Siawesh M; Mousavi M; Andreasen N; Nordberg A
J Alzheimers Dis; 2012; 28(2):443-58. PubMed ID: 22012848
[TBL] [Abstract][Full Text] [Related]
5. Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.
Gabriel AJ; Almeida MR; Ribeiro MH; Durães J; Tábuas-Pereira M; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
Neurosci Lett; 2017 Feb; 641():101-106. PubMed ID: 28108398
[TBL] [Abstract][Full Text] [Related]
6. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.
Sáez-Valero J; Fodero LR; Sjögren M; Andreasen N; Amici S; Gallai V; Vanderstichele H; Vanmechelen E; Parnetti L; Blennow K; Small DH
J Neurosci Res; 2003 May; 72(4):520-6. PubMed ID: 12704813
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
8. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
[TBL] [Abstract][Full Text] [Related]
9. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
10. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
11. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
[TBL] [Abstract][Full Text] [Related]
12. Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease.
Gabriel AJ; Almeida MR; Ribeiro MH; Carneiro D; Valério D; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
J Alzheimers Dis; 2018; 61(3):1097-1105. PubMed ID: 29254094
[TBL] [Abstract][Full Text] [Related]
13. Amyloid-β 1-42 levels are modified by apolipoprotein E ε4 in Creutzfeldt-Jakob disease in a similar manner as in Alzheimer's disease.
Varges D; Jung K; Gawinecka J; Heinemann U; Schmitz M; von Ahsen N; Krasnianski A; Armstrong VW; Zerr I
J Alzheimers Dis; 2011; 23(4):717-26. PubMed ID: 21157024
[TBL] [Abstract][Full Text] [Related]
14. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
[TBL] [Abstract][Full Text] [Related]
16. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
17. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
[TBL] [Abstract][Full Text] [Related]
19. APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease.
Reinvang I; Espeseth T; Westlye LT
Neurosci Biobehav Rev; 2013 Sep; 37(8):1322-35. PubMed ID: 23701948
[TBL] [Abstract][Full Text] [Related]
20. Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro.
Vuletic S; Peskind ER; Marcovina SM; Quinn JF; Cheung MC; Kennedy H; Kaye JA; Jin LW; Albers JJ
J Neurosci Res; 2005 May; 80(3):406-13. PubMed ID: 15795933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
